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Radix Puerariae lobatae (Gegen) 
suppresses the anticoagulation 
effect of warfarin: a pharmacokinetic 
and pharmacodynamics study
Beikang Ge†, Zhen Zhang† and Zhong Zuo*
Abstract 
Background: Radix Salvia miltiorrhiza (Danshen) and Radix Puerariae lobatae (Gegen) are used in Traditional Chinese 
Medicine to treat cardiovascular diseases. However, adverse herb-drug interactions were observed between warfarin 
and herbal remedies containing Danshen and Gegen. This study aims to investigate the pharmacokinetic and pharma-
codynamic interactions between warfarin and the different components found in Danshen and Gegen.
Methods: Sixty Sprague–Dawley rats were used to investigate the effects of warfarin (0.2 mg/kg), Danshen (240 or 
480 mg/kg) and Gegen (240 or 480 mg/kg) both in isolation and combination. The rats in the warfarin and Danshen/
Gegen combination groups were given an oral dose of Danshen or Gegen 2 h after being given an oral dose of warfa-
rin. After five consecutive days of treatment, the pharmacokinetic interactions between Danshen/Gegen and warfarin 
were investigated by simultaneously monitoring and comparing the cytochrome P450 (CYP) activities, mRNA and 
protein expression levels in the livers of the rats from the different treatment groups. The pharmacodynamic interac-
tions were evaluated by monitoring and comparing the vitamin K epoxide reductase (VKOR) activities, mRNA and 
protein expression levels in the livers of rats from the different groups, as well as the thrombomodulin (TM) activities, 
mRNA and protein in the lungs of these animals. The rat plasma soluble thrombomodulin concentrations of the differ-
ent treatment groups were also evaluated. Microsomes incubation, Real Time-Polymerase Chain Reaction and West-
ern blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM.
Results: The activities and expression levels of the CYP and VKOR enzymes in the warfarin-Gegen combination 
groups increased by nearly 30 % (P = 0.02) compared with the warfarin-alone group, whereas those of TM decreased 
by almost 25 % (P = 0.02). The administration of Danshen did not lead to any changes in the activities or the expres-
sion levels of the CYP, VKOR or TM enzymes compared with those of the control group. Gegen induced several 
warfarin-metabolizing CYP enzymes and neutralized the effects of warfarin towards VKOR and TM.
Conclusion: Gegen, rather than Danshen at the same tested dosage, offsets the anticoagulant effects of warfarin by 
accelerating the phase I liver metabolism of warfarin, as well as increasing the activity, mRNA and protein expression 
of VKOR while decreasing those of TM.
© 2016 Ge et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The use of the anticoagulant warfarin in combination 
with herbal remedies has caused several safety concerns 
because of the narrow therapeutic window of warfarin 
[1]. According to reports from pharmacists in the United 
Kingdom, about 58 % of patients prescribed warfarin also 
regularly consumed herbal medicines to manage their 
conditions [2, 3]. A racemic mixture of warfarin consists 
of a 1:1 mixture of its R- and S-enantiomers, which dif-
fer considerably in terms of their potency and the rate at 
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which they are metabolized [4]. Both of the enantiomers 
of warfarin are metabolized by cytochrome P450 (CYP) 
enzymes in a region- and stereo-selective manner, to 
afford the corresponding 6-, 7-, 8-, 10- and 4′-hydroxywar-
farin compounds as the major metabolites [5]. The inges-
tion of certain plant materials such as grapefruit [6] and 
garlic [7, 8] can have a pronounced effect on the activity 
and/or expression of the CYP enzymes, which could have 
serious consequences for the metabolism of warfarin. The 
co-administration of herbs and drugs can also affect the 
activity and expression of vitamin K epoxide reductase 
(VKOR), which is the target protein of warfarin in terms 
of its anticoagulant effects. Although there were two sep-
arate studies pertaining to the inhibitory activities of the 
drug-warfarin interactions of paracetamol and sodium 
dehydroacetate (DHA-S) towards VKOR [9, 10], there 
were studies concerning the impact of herbs on the activ-
ity or expression of VKOR. In addition to VKOR, plasma-
soluble thrombomodulin TM (sTM), which is the cleavage 
product of cellular TM [11], could be used as a potential 
biomarker for identifying patients at high risk of bleeding 
during warfarin treatment [12–14]. Notably, Salvianolic 
acid B led to an increase in the activity and expression of 
TM in  vitro [15]. Danshen-Gegen formula (DGF), which 
is a herbal medicine containing Radix Salvia miltiorrhiza 
(Danshen) and Radix Puerariae lobatae (Gegen), led to a 
5.36-fold increase in the mRNA expression of TM [16].
DGF, which is the aqueous extract derived of a 7:3 
(w/w) mixture of Danshen and Gegen, was recently devel-
oped in Hong Kong [17]. DGF contains a variety of active 
components, including danshensu, salvianolic acid B 
(SAB), protocatechuic aldehyde (PCA), puerarin, daid-
zin and daidzein [18], and was reported to be an effec-
tive agent for the treatment of cardiovascular diseases 
[19–21]. The results of our previous in vivo study in rats 
demonstrated that the co-administration of DGF with 
warfarin led to pronounced herb-drug interactions [22], 
including a significant decrease in the Cmax, area under 
curve (AUC) and the prothrombin (PT) time of warfarin. 
Although these changes in the pharmacokinetic prop-
erties of warfarin were attributed to the DFG-mediated 
induction of the CYP enzymes, the precise nature of 
the herbal components responsible for these induction 
effects were identified.
Danshen was reported to improve microcirculation, 
cause coronary vasodilation, suppress the formation of 
the thromboxane and inhibit the adhesion and aggrega-
tion of platelets. Based on its many interesting biological 
properties, Danshen has been widely used to treat coro-
nary artery disease and numerous other cardiovascular 
diseases in China, Korea and Japan, as well as several 
other Asian countries [23–25]. Although the results of 
several previous studies suggested that Danshen interacts 
with warfarin by changing its pharmacokinetic and phar-
macodynamic parameters [26–29], these studies gen-
erally fail to provide dosage information for Danshen. 
Furthermore, there are several inconsistencies in the 
findings of these studies. Preclinical studies in this area 
not reached an agreement on the effects of Danshen on 
the PT time of warfarin after the co-administration of 
these agents [30, 31]. The discrepancies observed in these 
pre-clinical and clinical research data could be explained 
in terms of the differences in the administration routes, 
dosages and Danshen preparations used in the differ-
ent studies. In this study, we used an ex  vivo approach 
to mimic the clinical behaviors of warfarin and Danshen 
and investigate the underlying mechanism of interac-
tion between these two agents. Compared with Danshen, 
there were very few reports pertaining to the herb-drug 
interactions of Gegen, which is another major compo-
nent of DGF. In a similar manner to Danshen, Gegen was 
reported to improve micro-circulation, increasing blood 
flow and preventing coronary artery disease [32]. Puera-
rin and Gegen extract were reported to regulate the activ-
ity of certain CYP enzymes in rats [33]. Furthermore, the 
results of a recent clinical study showed that puerarin 
induced the activity of CYP1A2 and inhibited the activ-
ity of CYP2D6 [34], which indicated that there could be 
potential interactions between warfarin and Gegen.
Existing mechanistic studies mainly focused on the 
impact of changes in the pharmacokinetics of warfa-
rin rather than its pharmacodynamics, despite the fact 
that changes in the latter account for 79.9  % of all the 
identifiable herb-drug interaction mechanisms [35]. 
This study aims to investigate the pharmacokinetic and 
pharmacodynamic interactions between warfarin and 
Danshen/Gegen. To achieve these goals, we applied an 
ex  vivo approach to investigate the effects of Danshen/
Gegen on the different CYP enzymes involved in the 
metabolism of warfarin (for pharmacokinetic analysis). 
We also monitored the effects of Danshen/Gegen on the 
activities and mRNA and protein expression levels of 
VKOR and TM (for pharmacodynamic analysis).
Methods
Herbs
The concentrated Chinese medicine granules of Dan-
shen (Batch No. 1007) and Gegen (Batch No. 1027) with 
the extraction ratio of 1:5 were purchased from Nong’s 
Company Limited (Hong Kong). The raw herbs were 
morphologically authenticated by an in-house herbal-
ist and chemically by the thin layer chromatography in 
accordance with the Chinese Pharmacopoeia 2005 [36]. 
The plant names in current study were used according 
to the latest revision in “The Plant List” (http://www.the-
plantlist.org).
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Reagents
Racemic warfarin, diclofenac sodium and naringin (inter-
nal standards) were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). The standards of sodium danshensu, 
protocatechuic aldehyde, SAB, puerarin, daidzin and 
daidzein were purchased from Zhongxin Innova Labo-
ratories (Tianjin, China). Phenobarbital (PB), beta-
naphthoflavone (BNF), cyclophosphamide monohydrate 
(CPA), bovine serum albumin, S-2238 and human 
thrombin were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Vitamin K1 purchased from Sigma was used 
to prepare vitamin K1 2, 3-epoxide (VKO) by the method 
of Tishler [37]. Hirudin was purchased from Calbio-
chem (La Jolla, California, USA). Acetic acid and ethyl 
acetate were obtained from BDH Laboratory (Poole, 
England). Acetonitrile and methanol (HPLC grade) were 
obtained from Tedia Company Inc. (Fairfield, USA) 
and Fisher Scientific UK Limited (Leicestershire, UK), 
respectively. All other reagents were analytical or HPLC 
grade. Distilled and deionized water was used for the 
preparation of all solutions. S-warfarin, R-warfarin, and 
racemic standards of 4′-, 6-, 7-, 8- and 10-OH-warfarin 
were purchased from Ultrafine Chemicals (Manches-
ter, UK). Both the primary and secondary antibodies of 
CYP1A1, CYP2B1/2B2, CYP2C6, CYP2C11, VKOR, TM 
and GAPDH were purchased from Abcam (Abcam Inc., 
Cambridge, MA). ELISA kits for detecting sTM plasma 
concentration were purchased from Life Science Inc.
Animals
Healthy male SD rats (220–250  g) were supplied by the 
Animal Service Center at the Chinese University of Hong 
Kong and fasted overnight before use. The experiments 
were carried out under the approval by the Animal Eth-
ics Committee of the Chinese University of Hong Kong 
with an approval number of (12-538) in DH/HA&P/8/2/1 
Pt.26 (Additional file 1).
Instruments for sample analyses
The LC/MS/MS system, used for sample analyses of 
warfarin and its monohydroxylated metabolites, were 
performed with an ABI 2000 tandem triple quadruple 
LC/MS spectrometer equipped with an electrospray 
ionization source (ESI), two Perkin-Elmer PE-200 series 
micro-pumps and auto-sampler (Perkin-Elmer, Norwalk, 
CT, USA). The liquid chromatographic sample analy-
ses instrument for detecting VK and VKO was a Waters 
HPLC system (Waters, Milford, MA,USA) equipped 
with 996 photodiode-array detector and 2695 separation 
module (pump and auto sampler). The chromatographic 
separation was performed at ambient temperature by 
X-Bridge™ C18 column (150 ×  4.6 mm i.d., 3.5 µm par-
ticle size). The auto-sampler was set at 4 °C. Acetonitrile/
isopropanol/water in a ratio of 100/8/2 (v/v/v) was 
used as mobile phase, with the flow rate of 1.2 mL/min. 
Absorbance of the eluting materials was measured at 
250  nm. The Bio-Rad microplate reader from BioRad 
(Benchmark, Japan) was used to analyze the optical des-
tiny of samples from ELISA and TM activity tests.
Standardization of Danshen and Gegen granules
Identification and quantification of the major compo-
nents in Danshen and Gegen granules were performed 
by Waters HPLC according to our previous study with 
modifications [22]. The chromatographic separation of 
the analytes was achieved by an Agilent Eclipse XDB-
C18 column (250 × 4.6 mm i.d., 5 μm particle size). The 
mobile phase consisting of 0.5  % acetic acid in acetoni-
trile (solvent A) and 0.5  % acetic acid in water (solvent 
B) was run with gradient elution at a flow rate of 1 mL/
min. The linear gradient elution was carried out as fol-
lows with a total running time of 90  min: solvent A 
was kept at 5  % for the first 5  min, and then increased 
to 10, 17, 35 and 90 % in the next 13, 12, 10 and 30 min, 
respectively, then returned to 5  % in 5  min and equili-
brated for 15 min before the next injection. HPLC analy-
ses indicated that the marker compounds (µg/100  mg 
granules, mean ± SD, n = 3) for Danshen granules were 
danshensu (1140.3  ±  24.6), SAB (821.3  ±  33.1), PCA 
(82.2  ±  4.6), and that for Gegen granules were puera-
rin (1314.9  ±  44.1), daidzein (74.4  ±  9.4) and daidzin 
(89.2 ± 7.2), respectively.
Animal treatments
The dosage of Danshen and Gegen for rats were both 
240 mg/kg/day (twice a day), which were calculated from 
its respective clinical therapeutic dose recommended by 
Chinese Pharmacopeia [36]. Since the clinical therapeu-
tic dosage of warfarin in common use was 1–2  mg/day 
for a person, the equivalent rats dosage was calculated to 
be 0.2 mg/kg (human equivalent dosage in rat = human 
dosage/60 kg × 6.2), once daily [38]. Healthy male SD rats 
were divided into nine groups (n = 6) and each group was 
treated for five consecutive days with different substance, 
including Danshen single dose (Danshen×1: 240  mg/
kg/day), Danshen double dose (Danshen×2: 480 mg/kg/
day), warfarin plus Danshen single dose (War  +  Dan-
shen×1: 0.2  +  240  mg/kg/day), warfarin plus Danshen 
double dose (War + Danshen×2: 0.2 + 480 mg/kg/day), 
Gegen single dose (Gegen×1: 240  mg/kg/day), Gegen 
double dose (Gegen×2: 480  mg/kg/day), warfarin plus 
Gegen single dose (War  +  Gegen×1: 0.2  +  240  mg/kg/
day), warfarin plus Gegen double dose (War + Gegen×2: 
0.2 + 480 mg/kg/day) and warfarin alone (War: 0.2 mg/
kg/day). Danshen/Gegen was given to rats twice daily. In 
the combination groups, Danshen/Gegen was given to 
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rats 2 h after the oral dosing of warfarin. In addition to 
the drug-treated groups, H2O, phenobarbital (PB 60 mg/
kg/day), beta-naphthoflavone (BNF 40  mg/kg/day) and 
cyclophosphamide (CPA 40  mg/kg/day) were also given 
orally for five consecutive days to rats that formed into 
one vehicle control and three positive controls (for deter-
mining the activity and expressions of CYPs) respec-
tively. Specifically, BNF for CYP1A1, PB for CYP2B1 and 
CYP2C6 and CPA for CYP2C11, were used to validate 
the assay. For the determining the activity and expres-
sions of VKOR and TM, warfarin was regarded as the 
positive control for the assay validation. Two hours after 
the last dosing, rats were sacrificed by decapitation. Liv-
ers, lungs and plasma were obtained from each rat for 
further treatment and assay.
Tissue sample preparations
Rat liver microsome (RLM) preparation
The rat livers were perfused by saline before being 
excided surgically on ice and cut into pieces for storage 
at −80 °C. The liver microsomes were prepared by series 
centrifugation as described previously [39]. Briefly, liver 
samples were thawed and weighed before homogeniza-
tion medium were added. The tissue was chopped using 
scissors and homogenized with an automatic homog-
enizer at 500  rpm (IKA Labortechnik, Staufen, Ger-
many). The resultant homogenates were transferred to 
clean centrifuge tubes, and centrifuged (Beckman Col-
ter, Inc, Fullerton, CA, USA) at 20,000×g for 20 min at 
4  °C. The supernatant was collected and further cen-
trifuged at 100,000×g for 1  h under 4  °C by the L8-70 
Beckman ultracentrifuge. The obtained microsomal 
pellet was re-suspended with homogenization medium 
and stored at −80 °C. Protein concentrations of the pre-
pared liver microsomes were determined by the Bio-
Rad protein assay kit (Bio-Rad Pacific Ltd, Hong Kong) 
and analyzed by the micro-plate reader (Benchmark, 
Japan) [40].
Extraction of TM from rat lungs
Rat lungs were perfused by saline before being excided 
surgically on ice and cut into pieces for storage at −80 °C. 
Pieces of lung were then homogenized in a glass tis-
sue grinder of 50 mL at 4 °C. Centrifuge was performed 
at 30,000×g for 40  min at 4  °C to get the pellet, which 
was re-suspended in 250  mL buffer (0.25  M sucrose, 
0.02 M Tris–HCl and 1 mM benzamidine-HCl, pH 7.5), 
homogenized, and centrifuged again as described above. 
The TM was finally extracted from the pellet by homog-
enization in 0.25  M sucrose, 0.02  M Tris–HCl, 1  mM 
benzamidine-HCl, and 0.5 % (v/v) Triton X-100, pH 7.5. 
This process was repeated three times and TM activity 
was assessed in the resulting extract [41]. The protein 
concentration of the extract was measured with Bio-Rad 
protein assay kit and adjusted to 100 ng/mL.
Methods for pharmacokinetic studies
CYP activities, mRNA and protein expressions in rat liver
Rat liver microsomal activities for mono‑hydroxylation 
of warfarin
The activities of rat liver microsomes for metabolizing 
warfarin were detected according to methods from our 
previous study [22]. A typical incubation (100  μL) con-
tained 50 mM Tris–HCl buffer (pH 7.4), 10 mM MgCl2, 
1.0  mg/mL microsomal protein, and racemic-, R- or 
S-warfarin as substrate respectively (5  μM for R- and 
S-warfarin, 10  μM for racemic warfarin). The mixture 
was pre-warmed in a 37 °C water bath with gentle shak-
ing for 10  min before addition of NADPH (final con-
centration of 1.0  mM) into the mixture to initiate the 
reaction. About 0.1 mL ice-chilled acetonitrile containing 
internal standard (2.0  μg/mL of diclofenac sodium) was 
added and incubated for another 30 min. After the mix-
ture centrifugation, the supernatant was subjected to LC/
MS/MS to compare the mono-hydroxywarfarin metabo-
lites (4′-, 6-, 7-, 8- and 10-hydroxywarfarin) among dif-
ferent treatment groups. The activities of CYPs could 
be expressed as the amount of mono-hydroxywarfarin 
metabolites formed.
CYP mRNA expression
Approximately 30  mg of rat livers were homogenized, 
and RNA was isolated with the Qiagen RNA extrac-
tion kit (Valencia, CA, USA). The quality of RNA was 
evaluated by measuring the 260/280 ratio (˃1.9) with an 
ultraviolet light spectrophotometer (Shimadzu, Japan). 
The sequence of the sense and antisense primers for rat 
CYP1A1 (FP: CCAAACGAGTTCCGGCCT; RP: TGCC 
CAAACCAAAGAGAATGA) [42], CYP2B1 (FP:AACCC 
TTGATGACCGCAGTAAA; RP: TGTGGTACTCCAAT 
AGGGACAAGATC) [42], CYP2C6 (FP: ATAAGACGCT 
TTACCCTCAC; RP: GATTTTCCTGCTTCCACTTA) 
[43], CYP2C11 (FP: TGCCCCCTTTTTACGAGGCT; RP: 
GGAACAGATGACTCTGAATTCT) [44] and GAPDH 
(FP: CAAGGTCATCCATGACAACTTTG; RP: GGGCC 
ATCCACAGTCTTCTG) [42] gene were designed as 
described previously. The reaction mixture system (final 
volume 20  µL) was prepared as follow: 4 units multi-
scribe reverse transcriptase, 1×RT buffer, 1  mM ran-
dom hexamer primers, 0.5  mM each of dATP, dGTP, 
dCTP and dTTP, and 10  mL total mRNA extract. The 
PCR involved an initiating heating for 10  min at 95  °C, 
40 cycles consisting of 10  s at 95  °C, 20  s at 60  °C, and 
a final extension step of 30  s at 72  °C. The fold change 
of target gene expression level in different drug treat-
ment groups (after correction with the level of GAPDH) 
Page 5 of 17Ge et al. Chin Med  (2016) 11:7 
was determined by the following equation: Fold 
change = 2−Δ(ΔCt), where ΔCt = Ct(target)−Ct(GAPDH) 
and Δ(ΔCt)  =  ΔCt(treated)−ΔCt(vehicle control) [22]. 
The Ct (cycle threshold) in the equation was defined as 
the number of cycles required for the fluorescent signal 
to cross the threshold.
CYP protein expression
The levels of CYP1A1, 2B1/2, 2C6, 2C11 and GAPDH 
proteins in rat liver microsomes obtained from different 
treatment groups were determined by Western blotting. 
Sodium dodecyl sulfate (SDS)–PAGE was performed by 
a Mini-Protean II system (Bio-Rad) as described previ-
ously [45]. After denaturing with sample buffer, rat liver 
microsomal proteins were separated in a 10  % (w/v) 
SDS–polyacrylamide gel and blotted onto a PVDF mem-
brane (Immobilon transfer membrane, Millipore, Bill-
erica, MA, USA). The membrane was blocked in 5  % 
defatted milk which was then incubated with the pri-
mary and secondary antibodies (horseradish peroxidase 
labeled anti-mouse or anti-rabbit IgG). The membrane 
was then immersed in the enhanced chemiluminescence 
solution (Millipore, Billerica, MA, USA) for 60 s. Digital 
chemiluminescence images were captured and analyzed 
by FluorChem Q Imaging System (Alpha Innotech Cor-
poration, Santa Clara, CA, USA).
Methods for pharmacodynamic studies
VKOR activity, mRNA and protein expression in rat livers
VKOR activity
Rat liver microsomes of different treatment groups were 
rinsed and re-suspended in the 0.02 M Tris–HCl buffer 
(pH 7.4) to obtain a microsomal protein concentration 
of 5  mg/mL 0.02  mL of this microsomal suspension 
was mixed with 0.071 mL of the 0.02 M Tris–HCl buff-
ered solution (pH 7.4). The mixture was pre-incubated 
for 3 min at 30 °C. Tris–HCl buffered solution (pH 7.4, 
2  µL 0.02  M) containing 0.1  M DTT (Sigma-Aldrich, 
St. Louis, MO, USA) were added, mixed and incubated 
for 5 min at 30 °C. Synthesized VKO (10 nM) in 2 µL of 
isopropanol was also added and subsequently incubated 
for 60  min at 30  °C. The reaction was stopped by the 
addition of 0.1  mL of ice-chilled isopropanol. Tocoph-
eryl acetate (2.5 µg; Sigma-Aldrich, St. Louis, MO, USA) 
in 0.2 mL of hexane was added as the internal standard. 
After vortex for 1  min, the mixture was centrifuged at 
15,000×g for 5 min. The hexane phase was evaporated 
to dryness with nitrogen [39]. The residue was dis-
solved in 150  µL mixed buffer containing acetonitrile/
isopropanol/water (100/8/2: v/v/v), and 10 µL was ana-
lyzed by HPLC. The amount of vitamin K1 formed was 
determined from the peak height ratio between vitamin 
K1/internal standard and a calibration graph. VKOR 
activity was expressed as the amount of vitamin K1 
formed.
VKOR mRNA and protein expression
The sequence of the sense and antisense primers for rat 
VKOR gene (VKORC1) used in RT-PCR was designed 
as described previously [46]. RT-PCR procedures for 
detecting mRNA expression of VKORC1 were same as 
that described for CYP mRNA expression. VKOR protein 
expression detection was conducted with the same oper-
ations for CYP protein expression.
TM activity, mRNA and protein expression in rat lung
TM activity
The ability of TM to accelerate protein C activation by 
thrombin was tested by a chromogenic assay as follow: 
0.5  M of purified protein C (Stago) in 100  µL of buffer 
was activated by 10 nM (1 NIH unit) of human thrombin 
(Sigma-Aldrich, St. Louis, MO, USA) in 10 µL of buffer 
in the presence of 5  mM calcium, 3  mg/mL of bovine 
serum albumin and of 50  µL of lung extracts from dif-
ferent substance treated groups. The final volume was 
200 µL. Incubation of the mixture lasted 30 min at 37 °C. 
The activation phase was stopped by adding 2 units of 
hirudin. The hydrolytic activity of the activated protein 
C (APC) thus generated was assessed by spectrophoto-
metric measurement at 405 nm of the rate of hydrolysis 
of D-Phe-Pip-Arg-pNA·2HCl, that is, S-2238. For this 
purpose, 800  µL of Tris–HCl buffer, pH 7.5, containing 
0.1  mM of S-2238 was added to the mixture (final vol-
ume: 1  mL). The changes in optical density per minute 
were converted into units of APC formed by referring 
to a standard curve constructed with concentrations of 
20, 40, 80, 160 and 320 n of standard APC (Stago). The 
activity of TM could be expressed as the amount of APC 
formed during incubation [47].
TM mRNA and protein expression
TM mRNA and protein (extracted from rat lung) expres-
sion were detected as that described for CYP. The 
sequence of the sense and antisense primers for rat TM 
used in RT-PCR was designed as described previously 
[48].
sTM plasma concentration analysis
After the animal treatment described previously, blood 
was collected using 3.8 % sodium citrate (sodium citrate: 
blood = 1:9) as an anticoagulant. Plasma was obtained by 
centrifuging the blood at 15,000×g for 3 min. The plasma 
samples were frozen and stored at −80  °C until the 
assay. An enzyme-linked immunosorbent assay (ELISA) 
was used to measure the plasma concentration of sTM. 
Standard sTM was series diluted to make a calibration 
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curve. The concentration of sTM was determined from 
the optical density of each sample at 450  nm against a 
calibration graph.
Statistical analysis
Data were expressed as the mean  ±  SD. Differences 
between two groups were analyzed by an unpaired stu-
dent’s t test. Differences between groups for continuous 
variables were evaluated by one way ANOVA with post 
hoc Tukey (when variances were equal according to Lev-
ene’s test) or Games-Howell test (when variances were 
not equal according to Levene’s test) [49]. P value less 
than 0.05 was considered as statistically significant.
Results
Pharmacokinetic mechanisms of warfarin‑Gegen 
interaction
Gegen induced the activities and mRNA expressions of different 
CYPs in rat liver
Induction on  CYP activities for  warfarin metabo-
lism When R-warfarin was used as the substrate (5 μM), 
the formation of all five mono-hydroxylated warfarin 
metabolites in the Gegen×1 and Gegen×2 groups increased 
significantly by 19–31 % (P = 0.03) and 24–30 % (P = 0.03), 
respectively, relative to the vehicle control group. Compared 
with the combined amount of all five mono-hydroxylated 
warfarin metabolites formed in the warfarin-alone group, 
there were significant increases in both of the combina-
tion groups (i.e., War + Gegen×1 and War + Gegen×2) of 
19–49 % (P = 0.02) and 22–49 % (P = 0.03), respectively. 
No significant differences were observed in the amounts of 
the mono-hydroxylated metabolites formed between the 
vehicle control and Danshen groups. In the positive control 
groups, the formation of 7- and 8-hydroxylated warfarin 
increased by 281 % (P < 0.001) and 242 % (P < 0.001) when 
the animals were treated with PB and BNF (positive controls 
for the activities of rat CYP2C6 and CYP1A1, respectively, 
contributing to the formation of 7- and 8-hydroxylated war-
farin) [22], respectively, compared with the results of the 
vehicle control group (Fig. 1).
When S-warfarin was used as a substrate (5  μM), the 
formation of the three detectable mono-hydroxylated war-
farin metabolites (i.e., 4′-, 6- and 7-hydroxylated warfarin) 
increased significantly by 14–16 % (P = 0.04) and 16–19 % 
(P  =  0.03) in the Gegen×1 and Gegen×2 groups, respec-
tively, compared with the vehicle control group. Compared 
with the combined amount of the 4′-, 6- and 7-monohy-
droxylated warfarin metabolites formed in the warfarin-
alone group, we observed significant increases of 17–19 % 
(P = 0.04) and 17–22 % (P = 0.03) in the formation of these 
metabolites in the Gegen×1 and Gegen×2 groups, respec-
tively. No inductive effects were observed in the Danshen-
treated groups based on a comparison of the warfarin 
metabolites formed in this group with those in the vehicle 
control group. In the positive control groups, the forma-
tion of 7-hydroxywarfarin increased by 237  % (P  <  0.001) 
when the rats were treated with PB (positive controls for rat 
CYP2C6, contributing to the formation of 7-hydroxywarfa-
rin) compared with the vehicle control group (Fig. 2). 
When racemic warfarin was used as the substrate 
(10  μM containing 5  μM of the R- and S-enantiomers) 
there were significant increases of 21–28  % (P  =  0.03) 
and 24–39 % (P = 0.02) in the formation of the 4′-, 6-, 7-, 
8- and 10-hydroxywarfarin metabolites in the Gegen×1 
and Gegen×2 groups, respectively, compared with the 
vehicle control group. Compared with the warfarin-
alone group, the co-administration of Gegen×1 and 
Gegen×2 with warfarin led to significant increases in the 
formation of all five mono-hydroxylated warfarin metab-
olites by 21–27  % (P  =  0.03) and 20–29  % (P  =  0.03), 
respectively. No inductive effect was observed when for 
the warfarin metabolites formed in the Danshen-treated 
groups based on a comparison of these results with 
those of the vehicle control group. In the positive control 
groups, the formation of the 7- and 8-hydroxywarfarin 
metabolites increased by 251  % (P  <  0.001) and 209  % 
(P < 0.001) when the rats were treated with PB and BNF, 
respectively, compared with the vehicle control group 
(Fig. 3). 
Induction of  the mRNA expression of CYP1A1, CYP2B1, 
CYP2C6 and  CYP2C11 Compared with the vehicle 
control group, there were significant increases of 260 % 
(P < 0.001) and 220 % (P < 0.001) in the mRNA expression 
levels of CYP1A1 and CYP2B1 in the Gegen×1 group, 
respectively. Similar increases of 250  % (P  <  0.001) and 
290  % (P  <  0.001) were also observed in the Gegen×2 
group, respectively (Fig. 4). However, these increases were 
small in size compared with those of the positive control 
groups. For example, BNF afforded a 8761-fold increase, 
whereas PB gave a 2812-fold increase. Compared with 
the mRNA expression ratio of CYP1A1 to CYP2B1 in the 
warfarin-alone group, there were significant increases 
(P  <  0.001) in the counterpart ratios of both combina-
tion groups (i.e., War + Gegen×1 and War + Gegen×2). 
For example, the former of these two groups (i.e., 
War + Gegen×1) showed 2.8- and 2.1-fold increases for 
CYP1A1 and CYP2B1, respectively, whereas the latter 
group (i.e., War  +  Gegen×2) showed 4.0- and 1.9-fold 
increases for CYP1A1 and CYP2B1, respectively. No 
inductive effects were observed in the mRNA expression 
levels of CYP1A1 and CYP2B1 when the Danshen-treated 
group was compared with the vehicle control group.
PB was used as a positive control to detect the mRNA 
expression of CYP2C6. Compared with the vehicle control 
group, there was a significant increase of 420 % (P < 0.001) 
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Fig. 1 Relative amount of formed monohydroxywarfarin (% of control) from different treatment groups. Using R-warfarin as substrate. *P < 0.05; 
**P < 0.01; ***P < 0.001, compared with the vehicle control group. #P < 0.05; ##P < 0.01; ###P < 0.001, compared with the warfarin alone group. 
&P < 0.05; &&P < 0.01; &&&P < 0.001, compared within same groups of different doses. Each point represents the mean ± SD (n = 6)
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in the mRNA expression ratio of CYP2C6 in the positive 
control group. Furthermore, the mRNA expression levels 
of CYP2C6 increased significantly by 1.4- and 1.5-fold in 
the Gegen×1 (P =  0.03) and Gegen×2 (P =  0.02) groups, 
respectively, compared with the vehicle control group. 
A significant 1.4-fold (P  =  0.03) increase in the mRNA 
expression level of CYP2C6 was also observed in both of 
the Gegen combination groups (i.e., War +  Gegen×1 and 
War + Gegen×2), compared with the warfarin-alone group. 
No significant differences were observed in the CYP2C6 
mRNA expression ratios between the Gegen×1 and 
Gegen×2 groups. Furthermore, no inductive effects were 
observed in the mRNA expression level of CYP2C6 for both 
doses of Danshen compared with the vehicle control group.
In terms of the mRNA expression of CYP2C11, we 
observed a slight increase of 1.07-fold in the Danshen×1 
group (P = 0.04) compared with the vehicle control group. 
A small increase of 117 % (P = 0.02) was also observed in 
the mRNA expression of CYP2C11 in the War + Gegen×1 
group compared to the warfarin-alone group.
No significant effects on the rat liver CYP protein expres-
sions Changes in the protein expression levels of the tar-
get CYP isozymes were determined to be minor compared 
with those observed for the metabolic activity and mRNA 
expression levels (Fig.  5). In the Gegen×1 and Gegen×2 
groups, the expression level of CYP2C6 protein appeared 
to increase compared with the vehicle control group, but 
this increase was not statistically significant. No induc-
tive effects were observed in the expression levels of any 
of the target CYP proteins in the Danshen-treated groups 
compared with the vehicle control group. In the posi-
tive control groups, the expression levels of the CYP1A1, 
CYP2B1/2B2 and CYP2C6 proteins increased significantly 
by 6.1- (P < 0.001), 5.6- (P < 0.001) and 1.7-fold (P = 0.003), 
respectively, compared with the vehicle control group.




































































































































































































































































































Fig. 2 Relative amount of formed monohydroxywarfarin (% of control) from different treatment groups. Using S-warfarin as substrate. *P < 0.05; 
**P < 0.01; ***P < 0.001, compared with the vehicle control group. #P < 0.05; ##P < 0.01; ###P < 0.001, compared with the warfarin alone group. 
&P < 0.05; &&P < 0.01; &&&P < 0.001, compared within same groups of different doses. Each point represents the mean ± SD (n = 6)
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Fig. 3 Relative amount of formed monohydroxywarfarin (% of control) from different treatment groups. Using racemic warfarin as substrate. 
*P < 0.05; **P < 0.01; ***P < 0.001, compared with the vehicle control group. #P < 0.05; ##P < 0.01; ###P < 0.001, compared with the warfarin alone 
group. &P < 0.05; &&P < 0.01; &&&P < 0.001, compared within same groups of different doses. Each point represents the mean ± SD (n = 6)
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Pharmacodynamic mechanisms of the 
warfarin‑Gegen interaction
Gegen led to an increase in the activity, as well as the 
mRNA and protein expression levels of VKOR in rat liver
Induction on VKOR activity
Compared with the vehicle control group, the Danshen×1 
and Danshen×2 groups showed no significant changes 
in their VKOR activity. In contrast, there were significant 
increases of 124.4 ± 6.3 % (P < 0.001) and 131.1 ± 12.9 % 
(P  <  0.001) in the VKOR activities of the Gegen×1 and 
Gegen×2 groups, respectively. Warfarin reduced the activ-
ity of VKOR by 52.4 ±  5.1  % (P  <  0.001) compared with 
the vehicle control group, which was consistent with its 
therapeutic effect. A comparison of the warfarin-alone 
group with the four different combination groups (i.e., 
War + Danshen×1; War + Danshen×2; War + Gegen×1; 
War + Gegen×2) revealed that Danshen had no impact on 
the VKOR activity during warfarin treatment. In contrast, 
the co-administration of Gegen with warfarin led to signifi-
cant increases of 35.9 ± 4.9 % (P < 0.001) and 36.2 ± 6.9 % 
(P < 0.001) in the VKOR activities of the War + Gegen×1 
and War + Gegen×2 groups, respectively. However, it was 
not possible to completely offset the inhibitory activity of 
warfarin towards VKOR using Gegen (Fig. 6).
Up‑regulation in the mRNA and protein expression levels 
of VKOR
Compared with the vehicle control group, there were no 
significant changes in the mRNA and protein expres-
sion levels of VKOR in the Danshen×1 and Danshen×2 
groups. In contrast, there were significant increases of 
116.1 ± 6.6 % (P < 0.001) and 123.0 ± 10.8 % (P < 0.001) 
in the mRNA expression of VKOR in the Gegen×1 and 
Gegen×2 groups, respectively, compared with the vehi-
cle control group. Significant increases of 123.9 ± 2.9 % 
(P  =  0.002) and 127.8  ±  5.7  % (P  =  0.002) were also 
observed in the expression levels of the VKOR protein 
in the Gegen×1 and Gegen×2 groups, respectively, com-
pared with the vehicle control group. Warfarin led to 
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Fig. 4 Rat liver mRNA expression (Fold of Control) for target CYP isoforms from different treatment groups. *P < 0.05; **P < 0.01; ***P < 0.001, com-
pared with the vehicle control group. #P < 0.05; ##P < 0.01; ###P < 0.001, compared with the warfarin alone group. &P < 0.05; &&P < 0.01; &&&P < 0.001, 
compared within same groups of different doses. Each point represents the mean ± SD (n = 6)
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71.6  ±  11.4  % (P  =  0.004) in the mRNA and protein 
expression levels of VKOR, respectively compared with 
the vehicle control group. Compared with the mRNA and 
protein expression levels of VKOR in the warfarin-alone 
group, there were significant increases (P < 0.001) of 27 % 
(mRNA expression) and 25 % (protein expression) in the 
corresponding Gegen combination groups, respectively. 
However, the co-administration of Danshen with warfa-
rin had no discernible impact of the mRNA or protein 
expression of VKOR (Fig. 7).
Gegen reduced the activity, as well as the mRNA and protein 
expression levels of TM in rat lung
Inhibition of the TM activity
Compared with the vehicle control group, there were 
no significant changes in the TM activities of the 
groups treated with Danshen or Gegen, although there 
did appear to be a decrease in the TM activities of the 
Gegen×1 and Gegen×2 groups. Warfarin led to a sig-
nificant increase of 125.7 ± 4.2 % (P < 0.001) in the TM 
activity compared with the vehicle control group. A 
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Fig. 5 Protein level (Fold of Control) for target rat liver CYP isoforms from different treatment groups. *P < 0.05; **P < 0.01; ***P < 0.001, compared 
with the vehicle control group. #P < 0.05; ##P < 0.01; ###P < 0.001, compared with the warfarin alone group. &P < 0.05; &&P < 0.01; &&&P < 0.001, com-
pared within same groups of different doses. Each point represents the mean ± SD (n = 6)
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comparison of the warfarin-alone group with the com-
bination groups (i.e., War  +  Danshen×1; War  +  Dan-
shen×2; War  +  Gegen×1; War  +  Gegen×2) showed 
that Danshen did not affect the activity of TM during 
warfarin treatment. In contrast, the co-administrating 
of Gegen with warfarin led to significant decreases of 
83.1 ± 3.2 % (P = 0.003) and 80.6 ± 2.9 % (P = 0.003) 
in the TM activities of the War  +  Gegen×1 and 
War + Gegen×2 groups, respectively. Gegen could there-
fore be used to offset the induction effect of warfarin 
towards TM activity (Fig. 8).
Down‑regulation of the mRNA and protein expression levels 
of TM
Compared with the vehicle control group, no sig-
nificant change was observed in the expression of the 
TM protein in the Danshen group, but we did observe 
an increase of almost 125  % (P  =  0.02) in the mRNA 
expression of TM. In contrast, significant decreases 
of 66.3 ± 1.5 % (P = 0.03) and 63.3 ± 7.5 % (P = 0.03) 
were observed in the mRNA expression levels of TM in 
the Gegen×1 and Gegen×2 groups, respectively, com-
pared with the vehicle control group. We also observed 
significant decreases of 67.6  ±  12.5  % (P  =  0.03) and 
63.3 ±  7.5  % (P =  0.03) in the expression levels of the 
TM protein in the Gegen×1 and Gegen×2 groups, 
respectively, compared with the vehicle control group. 
Significant increases of 141.9 ± 17.8 % (P = 0.003) and 
158.6 ± 8.2 % (P = 0.002) were observed in the mRNA 
and protein expression levels of TM in the warfarin-
alone group compared with the vehicle control group. 
Compared with the mRNA and protein expression lev-
els of TM in the warfarin-alone group, we observed 
decreases of nearly 25  % (P =  0.03, mRNA expression) 
and 12 % (P = 0.04, protein expression), respectively, in 
the Gegen combination groups. Notably, the co-admin-
istration of Danshen with warfarin had no discernible 
impact on the mRNA or protein expression levels of TM 













































































Fig. 6 Fold of change in VKOR activity from different treatment 
groups. *P < 0.05; **P < 0.01; ***P < 0.001, compared with the vehicle 
control group. #P < 0.05; ##P < 0.01; ###P < 0.001, compared with the 
warfarin alone group. &P < 0.05; &&P < 0.01; &&&P < 0.001, compared 
within same groups of different doses. Each point represents the 
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Fig. 7 Fold of change in VKOR mRNA (left) and protein (right) expression from different treatment groups. *P < 0.05; **P < 0.01; ***P < 0.001, com-
pared with the vehicle control group. #P < 0.05; ##P < 0.01; ###P < 0.001, compared with the warfarin alone group. &P < 0.05; &&P < 0.01; &&&P < 0.001, 
compared within same groups of different doses. Each point represents the mean ± SD (n = 6)
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Gegen led to a decrease in the plasma concentration 
of sTM
Compared with the vehicle control group, there were 
no discernible changes in the plasma concentration of 
sTM in the Danshen×1 and Danshen×2 groups. In con-
trast, significant decreases of 86.3  ±  1.5  % (P  =  0.01) 
and 86.5 ± 1.8 % (P = 0.01) were observed in the plasma 
concentrations of sTM in the Gegen×1 and Gegen×2 
groups, respectively. Warfarin led to an increase in the 
plasma concentration of sTM to 112.0 ± 3.2 % (P = 0.03) 
compared with the vehicle control group. A comparison 
of the warfarin-alone group with the different combina-
tion groups (i.e., War + Danshen×1; War + Danshen×2; 
War + Gegen×1; War + Gegen×2) showed that Danshen 
had no discernible impact on the plasma concentration of 
sTM during warfarin treatment. In contrast, significant 
decreases of 11.4 ±  1.7  % (P =  0.03) and 10.2 ±  1.5  % 
(P =  0.03) were observed in the plasma concentrations 
of sTM for the War  +  Gegen×1 and War  +  Gegen×2 
groups, respectively (Fig. 10).
Discussion
Danshen and Gegen elicit their effects by improving 
microcirculation and inhibiting platelet aggregation [24, 
32], whereas warfarin exerts its anticoagulant effect by 
inhibiting the activity of VKOR and inducing TM.
In the healthy Sprague–Dawley rats used in the cur-
rent study, Gegen rather than Danshen interacted with 
warfarin to offset its anticoagulant effects. In the Gegen-
warfarin interaction, Gegen could induce the phase I 
metabolism of warfarin in the liver by increasing the 
activities and mRNA expression levels of the differ-
ent CYP isozymes, as well as inducing the activity and 
expression levels of VKOR and inhibiting those of TM. 
The results of our previous study showed that the admin-
istration of a DFG-warfarin combination led to a reduc-









































































Fig. 8 Fold of change in TM activity from different treatment groups. 
*P < 0.05; **P < 0.01; ***P < 0.001, compared with the vehicle control 
group. #P < 0.05; ##P < 0.01; ###P < 0.001, compared with the warfarin 
alone group. &P < 0.05; &&P < 0.01; &&&P < 0.001, compared within 






































































































































































Fig. 9 Fold of change in TM mRNA (left) and protein (right) expression from different treatment groups. *P < 0.05; **P < 0.01; ***P < 0.001, compared 
with the vehicle control group. #P < 0.05; ##P < 0.01; ###P < 0.001, compared with the warfarin alone group. &P < 0.05; &&P < 0.01; &&&P < 0.001, com-
pared within same groups of different doses. Each point represents the mean ± SD (n = 6)
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of rats [23, 32]. Taken together with the results of the 
current study, it seems clear that these effects could be 
attributed to the Gegen present in DFG.
Although there were no clinical reports in the litera-
ture pertaining to the interactions between Gegen and 
warfarin, the results of several case reports indicated that 
Danshen can interact with warfarin in humans [20–22]. 
However, these reports are inconsistent with our current 
findings. This discrepancy could be caused by several dif-
ferent factors, including (1) the use of different sources 
and preparations of Danshen (e.g., differences in the 
quality of the herbal medicines/contamination profiles); 
(2) a lack of adequate information in the documented 
case report (e.g., only one case report failed to infer a 
causal relationship); and (3) differences in the nature of 
the animals used in the different studies (e.g., rats versus 
humans). CYP enzymes represent some of the most highly 
conserved entities among different species, with relatively 
small differences in the primary amino acid sequences of 
the CYP enzymes across different species [50, 51]. Human 
CYP2C9, CYP2C19, CYP1A1 and CYP1A2 play impor-
tant roles in warfarin metabolism, especially CYP2C9 [5], 
whereas the corresponding enzymes in rats are CYP2C11, 
CYP2C6, CYP1A1 and CYP2B1 (Fig.  11) [52]. Rat 
CYP1A1 shows a high level of conservation among spe-
cies with greater than 80  % sequence identity compared 
with the corresponding enzyme in humans [50, 51]. The 
6-, 7- and 8-mono-hydroxylated warfarin metabolites are 
formed by the CYP1A1 enzymes in rats and humans [50, 
51]. Furthermore, gene sequence similarities of 74–80 % 
were reported for the CYP2C11 and CYP2C6 enzymes in 


















































































Fig. 10 Fold of change in sTM plasma concentration from different 
treatment groups. *P < 0.05; **P < 0.01; ***P < 0.001, compared with 
the vehicle control group. #P < 0.05; ##P < 0.01; ###P < 0.001, compared 
with the warfarin alone group. &P < 0.05; &&P < 0.01; &&&P < 0.001, 
compared within same groups of different doses. Each point repre-










































































Major metabolic pathway Minor metabolic pathway
Metabolic pathway of warfarin in rat
Major metabolic pathway Minor metabolic pathway
Fig. 11 CYPs involved in warfarin metabolism in human and rat
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CYP2C subfamily (mainly CYP2C9 and 2C19) [50, 51]. 
The 4′-, 6- and 7-mono-hydroxylated warfarin metabo-
lites are mainly formed by CYP2C11 and CYP2C6 in 
rats. In humans, however, these metabolites are formed 
by CYP2C9, CYP2C19 and CYP2C18. Notably, a genetic 
similarity of 78  % was reported between the rat and 
human CYP2B1 enzymes, which are responsible for the 
formation of 4′-mono-hydroxylated warfarin [50, 51]. 
Based on the details provided above, CYP2C11, CYP2C6, 
CYP1A1 and CYP2B1 were selected in the current study 
to investigate warfarin-related interactions in a rat model. 
Although these isoforms are expressed in several different 
species, a high degree of similarity in their gene sequences 
between rats and human may not automatically result in 
similar levels of catalytic specificity and activity.
As well as assessing the impact of warfarin on the activ-
ities of CYPs, we also investigated the variability in the 
effects of warfarin in humans caused by polymorphisms 
in the CYP2C9 and VKORC1 genes [53]. Algorithms 
that integrate the relevant genetic and physical factors 
into comprehensive, individualized predictive models 
were used to predict warfarin dose [54]. Furthermore, 
physiological-based pharmacokinetic (PBPK) modeling 
and simulation software, including Simcyp, PK-Sim, Gas-
troPlus and MATLAB Sim-Biology, were recently made 
available to quantitatively predict the drug/herb-drug 
interactions of warfarin in humans based on rat data [54].
The results of an in  vitro study using HepG2 cells 
indicated that tanshinones could be used to induce the 
expression of CYP1A1 and CYP1A2 [55]. The treat-
ment of rats with Danshen, which mainly consists of 
danshensu, SAB and tanshinones, led to an increase in 
the activity and protein expression of CYP1A2. How-
ever, the activity of CYP1A2 did no change when rat 
hepatocytes were treated with danshensu or SAB in iso-
lation [56]. Furthermore, CYP1A-, CYP2C- and CYP3A-
inducing agents were found in the ethyl acetate extract, 
but not in the aqueous extract of Danshen [57]. Taken 
together, the results of these previous studies indicate 
that the lipophilic tanshinones in Danshen, rather than 
the hydrophilic components, were responsible for induc-
ing the activity and enhancing expression of the differ-
ent CYP isozymes. We found that the major components 
in Danshen granules were hydrophilic compounds, 
including danshensu (1140.3  ±  24.6  µg/100  mg gran-
ules), SAB (821.3 ±  33.1 µg/100 mg granules) and PCA 
(82.2  ±  4.6  µg/100  mg granules), which might explain 
why Danshen showed no effect on the CYP activities 
or expression levels. This finding is also supported by 
Yueng’s study, where the major tanshinone components 
rather than the aqueous extract of Danshen showed 
effects on warfarin hydroxylation in vitro and in vivo [58].
Although paracetamol and sodium dehydroacetate 
(DHA-S) were reported to interact with warfarin by inhib-
iting VKOR activity, leading to hemorrhage in Sprague–
Dawley rats, similar studies pertaining to the VKOR 
activity have never been conducted in context of herb-war-
farin interactions [9, 10]. Regarding the results of previous 
studies on TM, the treatment of H9c2 cells with DFG led to 
a 5.36-fold up-regulation in the mRNA expression of TM 
compared with a control system [16]. Furthermore, SAB led 
to an 1.25- and 1.8-fold increases in the activity and mRNA 
expression of TM, respectively, over the control levels in 
human umbilical vein endothelial cells [15]. In our study, 
the mRNA expression of TM in the Danshen-treated group 
was slightly higher than that of the vehicle control group. 
However, there were no significant differences in the activ-
ity and protein expression levels of TM between these two 
groups. The inconsistencies observed between our own 
findings and those reported by other researchers could be 
attributed to differences in the nature of the experiments. 
For example, SAB was directly loaded onto the cells used 
in Shi’s study at a high concentration (0.0125–0.5 mg/mL) 
[15]. However, SAB was reported to be poorly absorbed in 
animal studies and has an extremely low systemic bioavail-
ability [59]. In our study, although SAB was used as a major 
component of the Danshen granules, the in  vivo effects 
were very different to those observed in cells because of the 
poor absorption and bioavailability of SAB. Moreover, the 
other components in the herbs could also act on the CYP, 
VKOR and TM enzymes. All of these factors could there-
fore be considered as potential explanations for the discrep-
ancies observed between the in vitro and in vivo results.
Conclusion
Gegen, rather than Danshen at the same tested dosage, 
offsets the anticoagulant effects of warfarin by acceler-
ating the phase I liver metabolism of warfarin, as well as 
increasing the activity, mRNA and protein expression of 
VKOR while decreasing those of TM.
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